A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

Completed · Phase 1

Conditions studied: Renal Impairment

In brief

The primary objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with normal renal function and participants with various degrees of renal impairment.

Key facts

Study ID

NCT05489614

Run by

Amgen

People needed

33

Starts

2022-09-13

Expected to finish

2023-12-19

Last updated by the study team

2025-11-26

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

Where it is running

• Inland Empire Clinical Trials, LLC — Rialto, California, United States
• CRSCA HC LLC, dba Creekside Post Acute — Yucaipa, California, United States
• Clinical Pharmacology Of Miami, LLC — Miami, Florida, United States
• Advanced Pharma CR, LLC — Miami, Florida, United States
• Orlando Clinical Research Center — Orlando, Florida, United States
• Nucleus Network - Minneapolis — Saint Paul, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.